[go: up one dir, main page]

BR9910494A - Composições sólidas contendo derivados de ácido gama-aminobutìrico e processo para o seu preparo - Google Patents

Composições sólidas contendo derivados de ácido gama-aminobutìrico e processo para o seu preparo

Info

Publication number
BR9910494A
BR9910494A BR9910494-6A BR9910494A BR9910494A BR 9910494 A BR9910494 A BR 9910494A BR 9910494 A BR9910494 A BR 9910494A BR 9910494 A BR9910494 A BR 9910494A
Authority
BR
Brazil
Prior art keywords
preparation
compositions containing
acid derivatives
aminobutyric acid
solid compositions
Prior art date
Application number
BR9910494-6A
Other languages
English (en)
Other versions
BR9910494B1 (pt
Inventor
Akira Aomatsu
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15097099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9910494(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9910494A publication Critical patent/BR9910494A/pt
Publication of BR9910494B1 publication Critical patent/BR9910494B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçõES SóLIDAS CONTENDO DERIVADOS DE áCIDO GAMA-AMINOBUTìRICO E PROCESSO PARA O SEU PREPARO"<D>. A presente invenção proporciona uma composição sólida estabilizada contendo um derivado de ácido 4-amino-3-butanóico-substituído que pode ser obtido através da incorporação de um umectante como estabilizador.
BRPI9910494-6A 1998-05-15 1999-05-10 composições sólidas contendo derivados de ácido gama-aminobutìrico e processo para o seu preparo. BR9910494B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13311298 1998-05-15
PCT/US1999/010186 WO1999059572A1 (en) 1998-05-15 1999-05-10 Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same

Publications (2)

Publication Number Publication Date
BR9910494A true BR9910494A (pt) 2001-01-09
BR9910494B1 BR9910494B1 (pt) 2011-11-01

Family

ID=15097099

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9910494-6A BR9910494B1 (pt) 1998-05-15 1999-05-10 composições sólidas contendo derivados de ácido gama-aminobutìrico e processo para o seu preparo.

Country Status (24)

Country Link
US (1) US8623407B2 (pt)
EP (1) EP1077691B1 (pt)
JP (3) JP4564607B2 (pt)
KR (1) KR100669280B1 (pt)
CN (1) CN100337687C (pt)
AR (1) AR018609A1 (pt)
AU (1) AU769038B2 (pt)
BR (1) BR9910494B1 (pt)
CO (1) CO5060516A1 (pt)
CU (1) CU23051A3 (pt)
GT (1) GT199900068A (pt)
HU (1) HU228772B1 (pt)
ID (1) ID26395A (pt)
IS (1) IS2983B (pt)
MY (1) MY127953A (pt)
NO (1) NO329116B1 (pt)
PA (1) PA8472701A1 (pt)
PE (1) PE20000542A1 (pt)
PL (1) PL205145B1 (pt)
SV (1) SV1999000063A (pt)
TW (1) TW592691B (pt)
UY (1) UY25513A1 (pt)
WO (1) WO1999059572A1 (pt)
ZA (1) ZA200006483B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
ATE255891T1 (de) * 2000-06-16 2003-12-15 Teva Pharma Stabiles gabapentin, das mehr als 20 ppm chlor enthält
EP1430893A1 (en) * 2000-06-16 2004-06-23 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chloride ion
CA2411787C (en) * 2000-06-16 2007-03-20 Teva Pharmaceuticals Industries Ltd. Stable gabapentin having ph within a controlled range
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US20040018239A1 (en) 2000-11-17 2004-01-29 Hajime Ishida Pharmaceutical preparation containing copolyvidone
EP1558218A1 (en) * 2002-10-08 2005-08-03 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
ITMI20032399A1 (it) * 2003-12-09 2005-06-10 Zambon Spa Composizione farmaceutica contenente gabapentina.
WO2005077332A2 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Stable sustained-release oral dosage forms of gabapentin and process for preparation thereof
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2007083679A1 (ja) * 2006-01-20 2007-07-26 Dainippon Sumitomo Pharma Co., Ltd. 新規なフィルムコーティング錠
DE102007019071A1 (de) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
ES2623328T3 (es) * 2009-09-18 2017-07-11 Sitec Pharmabio Sl Procedimiento para la deshidratación de productos en polvo
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
AU2012222861A1 (en) * 2011-02-28 2013-10-17 Monash University Binder powders
US20160338949A1 (en) 2014-01-28 2016-11-24 Sun Pharmaceutical Industries Limited Stabilized gastroretentive tablets of pregabalin
HK1253735A1 (zh) 2015-05-26 2019-06-28 艾萨‧欧蒂迪 控制延缓释放普瑞巴林
JP7276760B2 (ja) * 2016-12-08 2023-05-18 日本ケミファ株式会社 ４－アミノ－３－ブタン酸類縁体含有固形製剤
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
JP2019052147A (ja) * 2017-09-13 2019-04-04 大原薬品工業株式会社 化学的な安定性が改善された、プレガバリン含有口腔内崩壊錠
JP7138666B2 (ja) * 2018-01-24 2022-09-16 大原薬品工業株式会社 γ－アミノ酪酸誘導体含有錠剤の化学的安定性を改善する方法
BR122022006356B1 (pt) * 2018-04-24 2022-10-04 Shionogi & Co., Ltd Forma de dosagem sólida
KR102501180B1 (ko) * 2018-04-24 2023-02-21 시오노기세야쿠 가부시키가이샤 안정성이 우수한 고형 제제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115553A (en) * 1973-12-10 1978-09-19 Armour Pharmaceutical Company Antacid tablets
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
GB8504093D0 (en) * 1985-02-18 1985-03-20 Ici Plc Alkene alkyne/cycloalkylene derivatives
US4486412A (en) * 1983-03-15 1984-12-04 Pharmacaps, Inc. Encapsulated antacid dispersions
CA1249968A (en) * 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
JPS63253022A (ja) * 1987-04-08 1988-10-20 Nitto Electric Ind Co Ltd バクロフエン外用製剤
PH26730A (en) 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
EP0458751A1 (en) * 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
DE9321574U1 (de) * 1992-03-11 2000-06-29 Asta Medica Ag, 01277 Dresden Tabletten, Granulate und Pellets mit hohem Gehalt an Wirkstoffen für hochkonzentrierte, feste Darreichungsformen
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder

Also Published As

Publication number Publication date
CU23051A3 (es) 2005-06-24
JP2000034227A (ja) 2000-02-02
AU769038B2 (en) 2004-01-15
IS5647A (is) 2000-09-29
PL344219A1 (en) 2001-10-08
JP3527729B2 (ja) 2004-05-17
HUP0101791A2 (hu) 2001-10-28
ZA200006483B (en) 2002-04-09
KR20010043610A (ko) 2001-05-25
MY127953A (en) 2007-01-31
SV1999000063A (es) 2000-07-31
HK1036407A1 (en) 2002-01-04
EP1077691A1 (en) 2001-02-28
GT199900068A (es) 2002-01-18
PA8472701A1 (es) 2000-09-29
PL205145B1 (pl) 2010-03-31
NO20005765L (no) 2000-11-14
AU4073399A (en) 1999-12-06
CN100337687C (zh) 2007-09-19
ID26395A (id) 2000-12-21
TW592691B (en) 2004-06-21
HU228772B1 (en) 2013-05-28
JP2003055211A (ja) 2003-02-26
WO1999059572A8 (en) 2000-12-21
IS2983B (is) 2017-09-15
JP2004043506A (ja) 2004-02-12
CN1575817A (zh) 2005-02-09
UY25513A1 (es) 1999-07-19
EP1077691B1 (en) 2008-09-10
US20090156677A1 (en) 2009-06-18
AR018609A1 (es) 2001-11-28
US8623407B2 (en) 2014-01-07
WO1999059572A1 (en) 1999-11-25
NO329116B1 (no) 2010-08-30
HK1072729A1 (zh) 2005-09-09
NO20005765D0 (no) 2000-11-14
JP4564607B2 (ja) 2010-10-20
KR100669280B1 (ko) 2007-01-17
PE20000542A1 (es) 2000-08-10
CO5060516A1 (es) 2001-07-30
JP3944150B2 (ja) 2007-07-11
BR9910494B1 (pt) 2011-11-01
HUP0101791A3 (en) 2003-03-28

Similar Documents

Publication Publication Date Title
BR9910494A (pt) Composições sólidas contendo derivados de ácido gama-aminobutìrico e processo para o seu preparo
BR9910508A (pt) Preparações farmacêuticas estabilizadas de derivados de ácido gama-aminobutìrico e processo para a sua preparação
BR9912073A (pt) Composições farmacêuticas que compreendem 2-quinolonas
BR9808438A (pt) Composição de barra
BR9913433A (pt) Sistema desinfetante estabilizado composto de duas partes e composições e métodos a ele relacionado
BR0206381A (pt) Derivados do ácido fumárico como inibidor de nf-kappab
BR9706629A (pt) Montagem de roda e pneu
BR0116369A (pt) Composto, método para a profilaxia ou o tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, uso de um composto, e, processo para preparar composto
BR0010242A (pt) Composições quìmicas que atraem artrópodes
BR0307875A (pt) Composição que pode ser administrada oralmente para a fotoproteção da pele
BR0113661A (pt) Composições farmacêuticas para a liberação tópica de inibidores da enzima ciclooxigenase-2
ES2164785T3 (es) Composiciones orales que contienen compuestos estannosos estabilizados.
ES2137456T3 (es) Agente de tratamiento de las enfermedades hepato-biliares.
ES2092266T5 (es) Composiciones para la nutricion ingeribles oralmente, que tienen apetibilidad mejorada.
BR9810312A (pt) Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico
ATE233543T1 (de) Kreatin, karnitin und/oder brenztraubensäure enthaltende kosmetische zusammensetzungen
AU5916998A (en) Non-irritating composition for treating acne and other skin conditions
BR9814523A (pt) &#34;composição farmacêutica contendo cloridrato de bupropion e um estabilizador de ácido inorgânico&#34;
ES2067448T3 (es) Amidas de acidos piridina-2,4- y -2,5-dicarboxilicos, procedimiento para su preparacion, utilizacion de las mismas, asi como medicamentos a base de estos compuestos.
BR9910329A (pt) Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BRPI0407652A (pt) método para acentuar a eficácia de um agente ativo, composição e método para produzir a composição
BR0008302A (pt) Uso de um derivado de benzaldeìdo, derivado de benzaldeìdo, composição farmacêutica, e, processo para a fabricação da mesma
BR9903585A (pt) Composição de borracha que contém material anti-reversão e pneu com com componente da mesma
BR9814772A (pt) Composições farmacêuticas sólidas que contêm miltefosina para administração oral no tratamento de leishmaniose

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO COM BASE NOS ARTIGOS 24 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/11/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2513 DE 06-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.